Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 11/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4201412 | 0.90 | ALDH1A1 (0.42) | ALDH1A1MAPK1KCNN4L3MBTL1TSHR | |
| SCHEMBL4202329 | 0.86 | MAPK1 (0.51) | ALDH1A1MAPK1KCNN4L3MBTL1TSHR | |
| SCHEMBL4203059 | 0.84 | ALDH1A1 (0.48) | ALDH1A1MAPK1KCNN4L3MBTL1NPSR1 | |
| SCHEMBL4210125 | 0.84 | KCNN4 (0.49) | ALDH1A1KCNN4NPSR1 | |
| SCHEMBL4205313 | 0.83 | ALDH1A1 (0.41) | ALDH1A1MAPK1KCNN4NPSR1TSHR | |
| SCHEMBL4205310 | 0.82 | KCNN4 (0.41) | ALDH1A1MAPK1KCNN4NPSR1 | |
| SCHEMBL4201420 | 0.82 | KCNN4 (0.53) | ALDH1A1KCNN4NPSR1TSHRKMT2A | |
| SCHEMBL4216678 | 0.80 | KCNN4 (0.40) | ALDH1A1MAPK1KCNN4TSHR | |
| SCHEMBL6049030 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MAPK1KCNN4L3MBTL1NPSR1 | |
| SCHEMBL4209121 | 0.79 | ALDH1A1 (0.45) | ALDH1A1MAPK1KCNN4L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579480-B2 | Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same | TOYO KASEI KOGYO COMPANY LIMITED (JP) | 2009-08-25 | — | — | US | disclosed |
| US-20070060630-A1 | Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same | TOYO KASEI KOGYO COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1650198-A1 | ALKOXYTETRAZOL-1-YLBENZALDEHYDE COMPOUND AND PROCESS FOR PRODUCING THE SAME | Toyo Kasei Kogyo Company Limited (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060630-A1 | Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same | ALDH7A1, NAT1, ARSA | ALDH1A1 4/4885MAPK1 1725/4885KCNN4 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.